Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines

被引：0

作者：

Hofer, Vivian ^{[1
]}

Wobser, Marion ^{[2
]}

Maurus, Katja ^{[3
]}

Houben, Roland ^{[2
]}

Schrama, David ^{[2
]}

Goebeler, Matthias ^{[2
]}

Rosenwald, Andreas ^{[3
]}

机构：

[1] Univ Hosp Wurzburg, Wurzburg, Germany

[2] Univ Hosp Wurzburg, Dermatol, Wurzburg, Germany

[3] Univ Wurzburg, Pathol, Wurzburg, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2023年 / 190卷

关键词：

D O I：

10.1016/j.ejca.2023.113044

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-156

引用

页码：S25 / S26

页数：2

共 50 条

[21] Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin
Rubio-Gonzalez, Belen
Zain, Jasmine
Garcia, Lino
Rosen, Steven T.
Querfeld, Christiane
JAMA DERMATOLOGY, 2016, 152 (12) : 1388 - 1390
[22] Phase II Trial Of Brentuximab Vedotin For CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
Duvic, Madeleine
Tetzlaff, Michael
Clos, Audra L.
Gangar, Pamela
Talpur, Rakhshandra
BLOOD, 2013, 122 (21)
[23] Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 10 - 11
[24] Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data
Enos, Tyler H.
Feigenbaum, Lawrence S.
Wickless, Heather W.
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (12) : 1400 - 1405
[25] Intralesional brentuximab vedotin: our experience in the treatment of CD30+primary cutaneous T-cell lymphomas
Arroyo Andres, J. A.
Rubio Muniz, C. A.
Agud De Dios, M. A.
Falkenhain Lopez, D.
Mitsunaga, K.
Sanchez Velazquez, A.
Postigo Llorente, C.
Ortiz-Romero, P. L.
EUROPEAN JOURNAL OF CANCER, 2022, 173 : S50 - S51
[26] Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
Kim, Hee Kyung
Moon, Seong Mi
Moon, Ji Hoon
Park, Jee Eun
Byeon, Seonggyu
Kim, Won Seog
BLOOD RESEARCH, 2015, 50 (04) : 254 - 256
[27] Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma
Elias, Alexandra
Marques-Piubelli, Mario L.
Nair, Ranjit
Prakash, Rishab
Ahmed, Sairah
Malpica, Luis
Lee, Hun Ju
Xu, Jie
Flowers, Christopher R.
Neelapu, Sattva S.
Vega, Francisco
Miranda, Roberto
Iyer, Swami P.
BLOOD, 2023, 142
[28] Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma
Hirai, Yoji
Sakurai, Jun
Yoshida, Shiho
Kikuchi, Takashi
Mitsuhashi, Toshiharu
Miyake, Tomoko
Fujimura, Taku
Abe, Riichiro
Fujikawa, Hiroki
Boki, Hikari
Suga, Hiraku
Shibata, Sayaka
Miyagaki, Tomomitsu
Shimauchi, Takatoshi
Kiyohara, Eiji
Kawakami, Yoshio
Morizane, Shin
JOURNAL OF DERMATOLOGY, 2024, 51 (08): : 1037 - 1049
[29] Rapid Response of locally distinct CD30 positive primary cutaneous anaplastic large T-Cell Lymphoma under Brentuximab Vedotin
Bender-Sabelkampf, S.
Berking, C.
Erdmann, M.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 50 - 50
[30] Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Muniesa, Cristina
Gallardo, Fernando
Garcia-Doval, Ignacio
Teresa Estrach, M.
Combalia, Andrea
Morillo-Andujar, Mercedes
De la Cruz-Vicente, Fatima
Machan, Salma
Moya-Martinez, Cristina
Rovira, Roger
Sanchez-Gonzalez, Blanca
Acebo, Elvira
Amutio, Elena
Penate, Yeray
Del Carmen Losada-Castillo, Maria
Pilar Garcia-Muret, M.
Iznardo, Helena
Roman-Curto, Concepcion
Canueto, Javier
Fernandez-de-Misa, Ricardo
Florez, Angeles
Maria Izu, Rosa
Torres-Navarro, Ignacio
Zayas, Ana
Perez-Paredes, Gema
Blanes, Mar
Ignacio Yanguas, J.
Perez-Ferriols, Amparo
Callejas-Charavia, Marta
Luis Ortiz-Romero, Pablo
Perez-Gil, Amalia
Prieto-Torres, Lucia
Gonzalez-Barca, Eva
Servitje, Octavio
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (01) : 57 - 64

← 1 2 3 4 5 →